Titan Pharmaceuticals
Titan Pharmaceuticals
TTNP
NASDAQ
6.13
USD
81.36%
About
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance.
The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus.
Its product development programs are in non-clinical stages of development..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.7M |
| Three Month Average Volume | 9.2M |
| High Low | |
| Fifty-Two Week High | 14.8 USD |
| Fifty-Two Week Low | 4.24 USD |
| Fifty-Two Week High Date | 20 Aug 2024 |
| Fifty-Two Week Low Date | 12 Jul 2024 |
| Price and Volume | |
| Current Price | 6.13 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.49% |
| Thirteen Week Relative Price Change | -12.02% |
| Twenty-Six Week Relative Price Change | -25.67% |
| Fifty-Two Week Relative Price Change | -52.32% |
| Year-to-Date Relative Price Change | -37.25% |
| Price Change | |
| One Day Price Change | 8.24% |
| Thirteen Week Price Change | -5.84% |
| Twenty-Six Week Price Change | -18.27% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -40.25% |
| Year-to-Date Price Change | -25.70% |
| Month-to-Date Price Change | 5.15% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 8.49904 USD |
| Book Value Per Share (Most Recent Quarter) | 4.3687 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 8.49904 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.3687 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -8.66866 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.24468 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00489 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -7.40559 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -6.58999 USD |
| Normalized (Last Fiscal Year) | -9.73936 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -7.40559 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -6.58999 USD |
| Including Extraordinary Items (Last Fiscal Year) | -7.40559 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -6.58999 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 8.65003 USD |
| Cash Per Share (Most Recent Quarter) | 4.4759 USD |
| Cash Flow Per Share (Last Fiscal Year) | -7.25665 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -6.63041 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -8.26297 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -583 |
| Cash Flow Revenue (Trailing Twelve Months) | -169,050 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -136,525.00% |
| Pretax Margin (Last Fiscal Year) | -3,026.63% |
| Pretax Margin (5 Year) | -406.26% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -3,954.89% |
| Operating Margin (Trailing Twelve Months) | -178,225.00% |
| Operating Margin (5 Year) | -425.20% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3,026.63% |
| Net Profit Margin (Trailing Twelve Months) | -136,525.00% |
| Net Profit Margin (5 Year) | -406.26% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -51.45% |
| Tangible Book Value (5 Year) | -0.56% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -51.16% |
| Revenue Change (Trailing Twelve Months) | -98.99% |
| Revenue Per Share Growth | -76.37% |
| Revenue Growth (5 Year) | -66.37% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -65.61% |
| Total Debt (5 Year) | -35.01% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -8.40% |
| EPS Change (Trailing Twelve Months) | 42.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -4,092,000 |
| Net Debt (Last Fiscal Year) | -6,260,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 30 |
| Price to Sales (Trailing Twelve Months) | 1.4K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 10 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 6 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -7,094,000 |
| Free Cash Flow (Trailing Twelve Months) | -6,762,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -310 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 8 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -91.72% |
| Return on Assets (Trailing Twelve Months) | -211.58% |
| Return on Assets (5 Year) | -96.80% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -139.16% |
| Return on Equity (Trailing Twelve Months) | -369.11% |
| Return on Equity (5 Year) | -216.72% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -138.02% |
| Return on Investment (Trailing Twelve Months) | -368.99% |
| Return on Investment (5 Year) | -156.65% |